These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 14718682

  • 1. Levodopa/carbidopa/entacapone (Stalevo).
    Hauser RA.
    Neurology; 2004 Jan 13; 62(1 Suppl 1):S64-71. PubMed ID: 14718682
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Entacapone/levodopa/carbidopa combination tablet: Stalevo.
    Drugs R D; 2003 Jan 13; 4(5):310-1. PubMed ID: 12952501
    [Abstract] [Full Text] [Related]

  • 7. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
    Silver DE.
    Expert Rev Neurother; 2004 Jul 13; 4(4):589-99. PubMed ID: 15853578
    [Abstract] [Full Text] [Related]

  • 8. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
    Castro A, Valldeoriola F, Linazasoro G, Rodriguez-Oroz MC, Stochi F, Marin C, Rodriguez M, Vaamonde J, Jenner P, Alvarez L, Pavon N, Macias R, Luquin MR, Hernandez B, Grandas F, Gimenez-Roldan S, Tolosa E, Obeso JA.
    Neurologia; 2005 May 13; 20(4):180-8. PubMed ID: 15891947
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV, Odinak MM, Mogil'naia VI, Sologub OS, Sakharovskaia AA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009 May 13; 109(1):51-4. PubMed ID: 19156087
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.
    Kuoppamäki M, Sauramo A, Korpela K, Vahteristo M, Kailajärvi M, Lehtinen T, Ellmén J.
    Int J Clin Pharmacol Ther; 2010 Nov 13; 48(11):756-60. PubMed ID: 20979935
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.
    Lyons KE, Pahwa R.
    Clin Neuropharmacol; 2006 Nov 13; 29(2):73-6. PubMed ID: 16614538
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.
    Kuoppamäki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J, Kaakkola S, Hänninen J, Löyttyniemi E, Kailajärvi M, Ruokoniemi P, Ellmén J.
    Eur J Clin Pharmacol; 2009 May 13; 65(5):443-55. PubMed ID: 19229530
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr 13; 14(76):51-4. PubMed ID: 15875340
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.